Clinical trials: Asthma Atopic
Asthma
Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma
The purpose of this study is to determine whether nocturnal environmental control with Temperature controlled Laminar Airflow (TLA) is effective as add on treatment in patients with perennial allergic asthma.
- Trial name
- 4A (NCT00986323)
- Testing
- Temperature controlled Laminar Airflow (TLA)
- Where
- 19 sites in Denmark, Finland and 4 more
- Volunteers
- 312 people
- Sponsor
- Airsonett AB
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (>18 years) with house dust mite allergy over a period of 12…
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
- Trial name
- CARIOCA (NCT03746860)
- Testing
- Tablet, Dispersible
- Where
- France
- Volunteers
- 1,508 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae
- Trial name
- NOVUS-UP (NCT07096440)
- Volunteers
- 105 people
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinoconjunctivitis
Multicenter Trial of Immunotherapy With House Dust Mite Allergoid
Multicenter Immunotherapy House Dust Mite Allergoid
- Trial name
- ACRI (NCT00540631)
- Testing
- specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinoconjunctivitis With or Without Allergic Asthma
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata
Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerized With Alternaria alternata in allergic patients
- Trial name
- NCT03604718
- Testing
- Beltavac® Polymerized with Alternaria alternata
- Where
- 13 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Probelte Pharma S.L.U.
Asthma
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
- Trial name
- NCT00046748
- Testing
- Omalizumab
- Volunteers
- 484 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR)…
- Trial name
- NCT06151938
- Testing
- Standardised allergen extract from house dust mites
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ALK-Abelló A/S
Rhinoconjunctivitis With or Without Allergic Asthma
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Cat Dander
Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerized With Cat Dander in allergic patients
- Trial name
- NCT04207697
- Testing
- Beltavac® Polymerized with cat dander
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Probelte Pharma S.L.U.
Healthy, Asthma
Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
The purpose of this study is to investigate the cytokine levels in nasal lavage and gene expression in nasal scraping following a single nasal dose of JNJ-43260295 in healthy participants, and in atopic mild to mild-persistent…
- Trial name
- NCT02243189
- Testing
- JNJ-43260295, Nasal Allergen Challenge
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Asthma
Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01577953
- Testing
- SB010
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Allergic Asthma
A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients
This study will assess the safety and tolerability of OM-85-IN compared to placebo in healthy volunteers and mild asthmatic patients
- Trial name
- NCT06486662
- Testing
- OM-85-IN
- Where
- Germany
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- OM Pharma SA
Asthma
A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma
This is a non-confirmatory, randomized, subject and investigator blinded, placebo-controlled, parallel-design, multi-center bronchoprovocation study.
- Trial name
- NCT03138811
- Testing
- CSJ117
- Where
- 10 sites in Canada, Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
- Conditions
- IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy, IgE-Mediated Cow Milk Allergy
- Trial name
- NCT07408869
- Testing
- Cizutamig
- Where
- Australia
- Sponsor
- Candid Therapeutics
Asthma
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
- Trial name
- SITAR (NCT01591044)
- Testing
- R940343 1mg, R940343 2mg
- Where
- 59 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Rigel Pharmaceuticals
Asthma
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with continued Xolair treatment.
- Trial name
- NCT00109200
- Testing
- Xolair (omalizumab)
- Sponsor
- Genentech, Inc.
Moderate to Severe Allergic Asthma
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
The study was designed to collect data about inadequately controlled moderate to severe allergic asthma in subjects 6 to < 12 years of age, managed in a real-world setting.
- Trial name
- NCT01362621
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 474 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control.
- Trial name
- NCT00264849
- Testing
- Omalizumab, Optimized asthma therapy
- Where
- 17 sites in Belgium, Canada and 15 more
- Volunteers
- 406 people
- Sponsor
- Novartis
Atopic Dermatitis, Eczema
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis.
- Conditions
- Atopic Dermatitis, Eczema, Asthma, Food Allergies
- Trial name
- NCT01577628
- Testing
- Lipikar Balm AP
- Where
- 4 sites in United States, Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Asthma
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
This study assessed the effect on asthma control of different dose levels and regimens of QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2 agonist medication. Safety was assessed also.
- Trial name
- NCT01716754
- Testing
- QGE031, Omalizumab
- Where
- 150 sites in United States, Argentina and 22 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Asthma
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
This study will evaluate the efficacy of QGE031 compared to omalizumab in patients with allergic asthma. Each treatment's effect in changing the concentration of inhaled allergen that is required to elicit a 15% fall in the…
- Trial name
- NCT01703312
- Testing
- QGE031, omalizumab
- Where
- 7 sites in Canada, Sweden
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals